YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Interaction of Nonsedating Antihistamines with Cerebral Muscarinic Receptors

비수기성 항 Histamine제와 대뇌 Muscarine 수용체와의 상호작용

  • Published : 1999.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

Nonsedating antihistamines do net cause sedation in therapeutic doses because these drugs hardly cross the blood-brain barrier. Since most of the peripheral side dffects of conventional antihistamines are related to their muscarinic receptor blocking action, the present study was performed to investigate whether nonsedating antihistamines interact with the muscarinic receptors and discriminate the muscarinic receptor subtypes in the rat cerebral microsomal fraction which containes both $M_1,{\;}M_2,{\;}M_3{\;}and{\;}M_4$ receptors. Five nonsedating antihistamines at high concentrations inhibited [$^3H$]QNB binding to the muscarinic receptor in a dose-dependent manner. The inhibition curves of these drugs except loratadine which showed positive cooperativity (nH=1.55) were steep (nH=1), indicating interaction with a single homogenous population of the binding sites. Astemizole, clemizole and mequitazine increased the $K_D$ value for [$^3H$]QNB without affecting the binding site concentrations, and this increase in the $K_D$ value resulted from the ability of these drugs to slow [$^3H$]QNB-receptor association. The Ki values of astemizole, clemizole and mequitazine for the inhibition for the inhibition of [$^3H$]QNB binding to muscarinic receptor were 0.58, 5.99 and $0.007{\;}{\mu}M$, respectively. However, loratadine and terfenadine inhibited noncompetitively [$^3H$]QNB binding with the normalized $IC_50$ value of about $2{\;}{\mu}M$. These results demonstrate that; 1) astemizole, clemizole and mequitazine interact directly with the muscarinic receptor at high concentrations; 2) muscarinic receptor blocking potency of these drugs varies widely among drugs; 3) these drugs do not discriminate between muscarinic receptor subtypes.

Keywords

References

  1. Current medical diagnosis and treatment Allergic and immunologic disorders Adelman, D. C.;Terr, A.;L. M. Tierney;S.J.McPhee;M. A. Apadakis (Eds.)
  2. Nature (Lond.) v.236 Definition and antagonism of histamine $H_2$-receptors Black, J.W.;Dunca, W.A.M.;Durant, C.J.;Ganellin, C.R.;Parsons, E.M.
  3. Am. Fam. Physician v.52 no.2 Antihistamines : The old and the new Peggs, J. F.;Shimp, L. A.;Opdycke, R. A.
  4. Drug Evaluations Annual Histamine and antihistamines Ambre, J. J.;Bennet, D. R.;Cranston, J. W.;Dickinson,B. D.;Mark,E. R.;Glade,M. J.;Kosman, M. E.;Lampe, K.F.;McCann, M. A.;Pang, S. J.;Weaver, R. H.
  5. Drugs v.12 Antimotion siknee and antiemetic drugs Wood, C. D
  6. Drugs v.17 Antimotion sickness and antiemetic drugs Wood, C. D.
  7. Drugs v.30 Newer non-sedating antihistamines, will replace order agent? Brandon, M. L.
  8. J. Am. Acad. Dermatol. v.24 Treatment of urticaria and angioedema : Low-sedating H1-type antihistamines Soter, N. A.
  9. J. Allergy clin. immunol. v.86 $H_1$-receptor antagonist treatment of seasonal allergic rhinitis Kaiser, H. B.
  10. Dermatol. Clin v.9 Antihistamine update Herman, L. E.;Bernhard, J. D.
  11. Allergy and clinical immunology v.86 Recent advances in $H_1$-receptor antagonist treatment Simons, F. E. R.
  12. J. Am. Acad. Dermatol v.19 Review of nonsedating H1 antihistamines in treatment Monroe, E. W.
  13. J. Pharmacol. Exp. Ther. v.242 Selectivity of muscarinic antagonist in radioligand and in vivo experiment for the putative $M_1,M_2 and M_3$ receptors Doods, H. N.;Mathy, M. J.;Davidesko, D.;van charldorp, K. J.;de Jonge, A.;van zwieten, P. A.
  14. Br. J. Pharmacol. v.86 Action of agonist and antagonists at muscarinic receptors present on ileum and atria in vitro Clague, R. V.;Eglen, R. M.;Strachan, A. C.;Whiting, R. L.
  15. Br. J. Pharmacol. v.90 Competitive and noncompetitive antagonism exhibited by 'selective' antagonist at atrial and ileal muscarinic receptor subtypes Eglen, R. M.;Whiting, R. L.
  16. Facts Book The G-protein linked receptor Watson, S.;Arkistall, S
  17. Life sci v.56 no.s11/12 The design of novel methoctramine-related tetraamines as muscarinic receptor subtype selective antagonists Mechioore, C.;Minarini, A.;Budriesi, R.;Chiarini A.;Spampinato S.;Tumiatti V.
  18. Life sci v.60 no.13-14 The $M_5$(m5) receptor subtype : fact or fiction? Reever C. M.;Ferrari-DiLeo G.;Flymn D. D.
  19. Yakhak Haeji v.32 Action on the cardiac muscarinic receptor Lee, S. W.;Park, Y. J.;Lee, J. S.;Ha, K. W.;Jin, K. D.
  20. Yakhak Hoeji v.37 Relative potency of antihistaminics for H1- and muscarinic receptor Lee, S. W.;Park, Y. H.;Lee, J. S.
  21. J. Pharmacol. Methods v.7 A simple method for the purification of rat brain $Na^+,K^+-adenosine triphosphatase(ATPase) Mayrand, R. R.;Fullerton, D. S.;Ahemd, K.
  22. J. Biol. Chem. v.193 Protein measurement with the folin-phenol reagent Lowy, O. H.;Rosebrough, N. J.;Farr, A. L.;Randall, R. J.
  23. J. Biol. Chem. v.249 Nature of the transport ATPase-digitalis complex. X. Thermodynamics of the rate of ouabain binding Wallick, E. T.;Schwartz, A
  24. Acad. Sci v.5 The attraction of proteins for small molecules and ions Ann N. Y. Scatchard, G
  25. Biochem. Pharmacol. v.22 Relationship between the inhibition constant (ki) and the concentration of inhibition of which cause 50 percent inhibition $(I_50)$ of an enzymatic reaction Cheng, Y.C.;Prusoff, W.H.
  26. J. Clin pharmacol. v.27 Pharmacokinetics and dose proportion-ality of loratadine Hilber, J.
  27. Present at allergy council of america symposium How antihitamines act on the central nervous system Gengo, F. M.
  28. Proc. Nat. Acad. Sci. U.S.A. v.71 no.5 Muscarinic cholinergic binding rat brain Yamamura, H. I.;Snyder, S. H.
  29. J. Pharmacol. Exp. Ther. v.228 no.3 Comparison of [^3H] pirenzepine and [^3H]quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rat brain Luthin, G. R.;Wolfe, B. B.
  30. Arznein-Forsch/Drug Res v.36 Animal pharmacology of the selective histamine $H_1$-receptor antagonist tazifylline Poizot, A.;Dumez, D.;Ferrandon, P.;Lefournier, C;Michel, A;Armstrong, J. M.
  31. Mol. Pharmacol. v.21 In vitro and in vivo binding charateristics of a new long-acting histamine $H_1$-receptor antagonist tazifyline Poizot, A.;Dumez, D.;Ferrandon, P.;Lefournier, C.;Michel, A.;Armstrong, J. M.
  32. Mol. Pharmacol. v.26 $[^3H]$Pirenzepine and $[^3H]$QNB binding to brain muscarinic receptors. Differences in measured receptor density are not explained by difference in receptor isomerization Luthin, G. R.;Wolfe, B. B.
  33. Mol.Pharamacol. v.27 Bisquaternary pyridium oximes as allosteric inhibitors of rat brain muscarinic receptors Kloog, Y.;Sokolovsky, M.
  34. J. Pharmacol. Exp. Ther. v.236 Stabilization of antagonist binding to cardiac muscarinic acetlcholine receptor by gallamine and other neuromuscular blocking drug Nedoma, J.;Tucek, S.;Danilov, A. F.;Shelkovnikov, S. A.
  35. Biochem. Biophys. Commum v.121 Effects of verapamil on the binding properties of rat heart muscarinic receptors.:Evidence for an allosterteric site Waelbroeck M.;DeNeef, P.;Roberecht, P.;Christophe J.
  36. Yakhak Hoeji v.34 no.4 Interatction of antihistaminics with muscarinic receptor(II) : Action on the cerebral muscarinic $M_!$ receptor Lee, S. H.;Park, Y. J.;Park, I. S.;Lee, J. S.